RG

Redmile Group Portfolio holdings

AUM $1.49B Turnover 10.26%
1-Year Est. Return 208.7%
This Fund
S&P 500
This Quarter Est. Return
+15.59%
1 Year Est. Return
+208.7%
3 Year Est. Return
+777.5%
5 Year Est. Return
+1,114.43%
10 Year Est. Return
+23,630.52%
AUM
$664M
AUM Growth
+$96.5M
Cap. Flow
+$35.6M
Cap. Flow %
5.35%
Top 10 Hldgs %
45.17%
Holding
73
New
23
Increased
14
Reduced
10
Closed
23
Avg Time Held Equity + Options
0.1 years
Top 10 Avg Time Held Equity + Options
0.1 years
Top 20 Avg Time Held Equity + Options
0.1 years
Avg Time Held Equity only
0.1 years
Top 10 Avg Time Held Equity only
0.1 years
Top 20 Avg Time Held Equity only
0.1 years

Top Buys

Rank Stock Value
1
AMGN icon
Amgen
AMGN
+$37.5M
2
AGN
Allergan plc
AGN
+$36.2M
3
STJ
St Jude Medical
STJ
+$33.9M
4
GILD icon
Gilead Sciences
GILD
+$31.7M
5
CBST
CUBIST PHARMACEUTICALS INC
CBST
+$27.4M

Top Sells

Rank Stock Value
1
ALGN icon
Align Technology
ALGN
+$38.8M
2
ONXX
ONYX PHARMACEUTICALS INC
ONXX
+$34.2M
3
CAH icon
Cardinal Health
CAH
+$27.6M
4
IPXL
Impax Laboratories, Inc.
IPXL
+$19.2M
5
CELG
Celgene Corp
CELG
+$14.3M

Sector Composition

Rank Sector Weight
1 Healthcare 80.5%
2 Miscellaneous 17.62%
3 Consumer Staples 1.19%
4 Technology 0.69%
5 Communication Services 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow Held Since
AGN
1
DELISTED
Allergan plc
AGN
$39.1M 5.89%
+271,500
New +$36.2M
2013 Q3
0 quarters
AMGN icon
2
Amgen
AMGN
$230B
$38.7M 5.83%
+345,700
New +$37.5M
2013 Q3
0 quarters
STJ
3
DELISTED
St Jude Medical
STJ
$35.3M 5.32%
+658,000
New +$33.9M
2013 Q3
0 quarters
GILD icon
4
Gilead Sciences
GILD
$190B
$33.3M 5.01%
+529,800
New +$31.7M
2013 Q3
0 quarters
CBST
5
DELISTED
CUBIST PHARMACEUTICALS INC
CBST
$28.8M 4.33%
+452,600
New +$27.4M
2013 Q3
0 quarters
CLVS
6
DELISTED
Clovis Oncology, Inc.
CLVS
$28.6M 4.31%
471,345
-4,032
-0.8% -$286K
2013 Q2
1 quarter
REGN icon
7
Regeneron Pharmaceuticals
REGN
$80.1B
$25.2M 3.79%
80,400
+19,400
+32% +$5.1M
2013 Q2
1 quarter
THC icon
8
Tenet Healthcare
THC
$21.9B
$24.3M 3.67%
591,000
+274,800
+87% +$11.5M
2013 Q2
1 quarter
CTRX
9
DELISTED
CATAMARAN CORP COM STK (CDA)
CTRX
$23.3M 3.52%
+508,100
New +$26.8M
2013 Q3
0 quarters
ARIA
10
DELISTED
Ariad Pharmaceuticals Inc
ARIA
$23.3M 3.5%
1,264,009
-13,100
-1% -$254K
2013 Q2
1 quarter
ARRY icon
11
DELISTED
Array Biopharma Inc
ARRY
$22.8M 3.44%
3,669,593
-1,099,775
-23% -$6.53M
2013 Q2
1 quarter
PODD icon
12
Insulet
PODD
$9.29B
$21.7M 3.27%
599,000
+25,700
+4% +$862K
2013 Q2
1 quarter
BKD icon
13
Brookdale Senior Living
BKD
$2.41B
$19.9M 3%
757,800
+211,300
+39% +$5.79M
2013 Q2
1 quarter
PBYI icon
14
Puma Biotechnology
PBYI
$527M
$18.3M 2.75%
340,165
-199,829
-37% -$10.8M
2013 Q2
1 quarter
HCA icon
15
HCA Healthcare
HCA
$102B
$17.7M 2.67%
414,400
-318,900
-43% -$12.5M
2013 Q2
1 quarter
NUVA
16
DELISTED
NuVasive, Inc.
NUVA
$17M 2.56%
693,392
-70,600
-9% -$1.74M
2013 Q2
1 quarter
CELG
17
DELISTED
Celgene Corp
CELG
$15.2M 2.29%
197,200
-204,600
-51% -$14.3M
2013 Q2
1 quarter
ZTS icon
18
Zoetis
ZTS
$31.1B
$14.5M 2.18%
+465,900
New +$14.3M
2013 Q3
0 quarters
CMRX icon
19
DELISTED
Chimerix, Inc.
CMRX
$14.4M 2.16%
653,705
+202,905
+45% +$4.17M
2013 Q2
1 quarter
CERS icon
20
Cerus
CERS
$451M
$13.8M 2.07%
2,052,400
-373,000
-15% -$2.03M
2013 Q2
1 quarter
HTWR
21
DELISTED
HEARTWARE INTERNATIONAL INC COM STK (DE)
HTWR
$13.6M 2.04%
185,125
+22,800
+14% +$1.94M
2013 Q2
1 quarter
MRK icon
22
CALL
Merck
MRK
$364B
$13.4M 2.03%
296,060
+34,060
+13% +$1.56M
2013 Q2
1 quarter
GMED icon
23
Globus Medical
GMED
$10.2B
$12.9M 1.94%
736,100
+35,400
+5% +$613K
2013 Q2
1 quarter
SNDA icon
24
Sonida Senior Living
SNDA
$1.72B
$12.6M 1.9%
39,820
+11,633
+41% +$3.94M
2013 Q2
1 quarter
AZN icon
25
AstraZeneca
AZN
$251B
$12.3M 1.85%
+236,100
New +$11.9M
2013 Q3
0 quarters
1
2 3

Similar funds

FCM
Fairholme Capital Management South Miami, Florida $1.49B AUM 28.35% 1-Year Est. Return
MM
Main Management San Francisco, California $1.49B AUM 22.28% 1-Year Est. Return
WA
WBH Advisory Baltimore, Maryland $1.49B AUM 20.41% 1-Year Est. Return
ACB
Aristotle Capital Boston Boston, Massachusetts $1.49B AUM 32.81% 1-Year Est. Return
LCS
Levin Capital Strategies New York $1.49B AUM 30.44% 1-Year Est. Return
GAM
Gemmer Asset Management Walnut Creek, California $1.49B AUM 42.66% 1-Year Est. Return
MFWP
Mosaic Family Wealth Partners St. Louis, Missouri $1.49B AUM 26.43% 1-Year Est. Return
PMG
ProVise Management Group Clearwater, Florida $1.49B AUM 21.79% 1-Year Est. Return

Redmile Group's Q3 2013 Portfolio in Review

As of Q3 2013, Redmile Group held 73 positions worth $664M, up 17% from $568M the previous quarter. Its ten largest holdings account for 45% of the portfolio.

Redmile Group deployed $35.6M of net new capital in Q3 2013, opening 23 new positions and adding to 14 existing holdings. Its largest new stake was Amgen: 345,700 shares worth $38.7M.

By sector, the portfolio is most concentrated in Healthcare at 80% of assets, down from 81% a quarter earlier, followed by Miscellaneous and Consumer Staples.

On the sell side, the largest reduction was Celgene Corp, an estimated $14.3M trimmed.

  • Redmile Group's largest Q3 2013 buy was Amgen: 345,700 shares worth $38.7M.
  • Redmile Group added most to Tenet Healthcare in Q3 2013, an estimated $11.5M increase.
  • Redmile Group's biggest Q3 2013 reduction was Celgene Corp, cutting an estimated $14.3M.
  • Redmile Group fully exited Align Technology in Q3 2013, selling an estimated $38.8M.
  • Redmile Group's ten largest holdings make up 45% of its $664M portfolio in Q3 2013.
  • Redmile Group opened 23 new positions and closed 23 in Q3 2013.
  • Redmile Group's portfolio value rose 17% quarter-over-quarter to $664M.

Based on Redmile Group's 13F filing for Q3 2013, filed 14 Nov 2013.